Investors Suffering Significant Losses in Unicycive Therapeutics, Inc. Notified: Bronstein, Gewirtz & Grossman LLC Unveils Possibility of Class Action Lawsuit Filing

In a recent development, a class action lawsuit has been filed against Unicycive Therapeutics, Inc. and certain of its officers. The lawsuit seeks to recover damages for alleged violations of federal securities laws.

During the Class Period, which spans from March 29, 2024, to June 27, 2025, it is alleged that Unicycive's executives made false and misleading statements about the company's business, operations, and compliance policies. Specifically, the lawsuit alleges that the company's regulatory prospects, particularly its readiness and ability to satisfy FDA's manufacturing compliance requirements, were overstated.

If you purchased Unicycive securities during the Class Period, you can join this case by visiting bgandg.com/UNCY. There is no cost to you to be a part of this class action lawsuit.

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits, is handling this case. The firm has recovered hundreds of millions of dollars for investors nationwide.

If you suffered a loss in Unicycive, you have until October 14, 2025, to request that the Court appoint you as lead plaintiff. To learn more or to discuss your legal options, you can visit bgandg.com/UNCY or contact Peretz Bronstein, Esq. or Nathan Miller at 332-239-2660.

It is important to note that no court authority has yet investigated Unicycive Therapeutics, Inc. and its accused executives for violations of securities law regulations. Attorney advertising. Prior results do not guarantee similar outcomes.

For updates on this case, you can follow Bronstein, Gewirtz & Grossman, LLC on LinkedIn, Facebook, or Instagram. The firm operates on a contingency fee basis, meaning they will be reimbursed for out-of-pocket expenses and attorneys' fees from the total recovery only if they are successful.

This article is for informational purposes only and should not be taken as legal advice. If you have any questions or concerns, we encourage you to seek legal counsel.

Investors Suffering Significant Losses in Unicycive Therapeutics, Inc. Notified: Bronstein, Gewirtz & Grossman LLC Unveils Possibility of Class Action Lawsuit Filing